New Drugs and Targets for Asthma and COPD

Description

Asthma, allergy and chronic obstructive lung disease are common throughout the world and are increasing in incidence, particularly in the developing world. This volume provides a state-of-the-art account of the identification of new targets and the development of new therapies for these conditions. Some 40 chapters by clinical academics and senior members of the pharmaceutical industry detail the latest breakthroughs in research and development. In asthma, a promising approach is the use of therapy directed against specific Th2 responses through biological antagonists of IL-5, IL-4 and IL-13. There have also been major advances in our understanding of innate immune responses to pathogen-associated molecular patterns, and in the area of Toll-like receptors.
Up to date and comprehensive, this book will be of particular relevance to those working in the pharmaceutical industry (in preclinical research and clinical development), to academic researchers in the field of respiratory medicine, and to respiratory health care specialists.

Informations

• Publié par: S. Karger AG
• Date de parution: 31 août 2010
• Nombre de lectures: 0
• EAN13: 9783805595674
• Langue: English
• Poids de l'ouvrage: 2 Mo

Extrait

New Drugs and Targets for Asthma and COPD
Progress in Respiratory Research
Vol. 39
Series Editor
Chris T. Bolliger     Cape Town
 
New Drugs and Targets for Asthma and COPD
Volume Editors
Trevor T. Hansel     London
Peter J. Barnes     London
80 figures, 67 in color, 46 tables, 2010
Dr. Trevor T. Hansel Imperial Clinical Respiratory Research Unit (ICRRU) of St. Mary's Hospital at National Heart and Lung Institute Imperial College Paddington London W2 1NY (UK)
Prof. Peter J. Barnes National Heart and Lung Institute Imperial College Royal Brompton Hospital London SW3 6LY (UK)
Library of Congress Cataloging-in-Publication Data
New drugs and targets for asthma and COPD / volume editors, Trevor T. Hansel, Peter J. Barnes.
p. ; cm. –– (Progress in respiratory research, ISSN 1422-2140 ; v. 39)
Includes bibliographical references and index.
ISBN 978-3-8055-9566-7 (hardcover: alk. paper) –– ISBN 978-3-8055-9567-4 (e-ISBN)
1. Asthma-Chemotherapy. 2. Antiasthmatic agents. I. Hansel, T.T. (Trevor T.), 1956- II. Barnes, Peter J., 1946- III. Series: Progress in respiratory research ; v. 39. 1422-2140
[DNLM: 1. Asthma-drug therapy. 2. Pulmonary Disease, Chronic Obstructive-drug therapy. 3. Respiratory System Agents. W1 PR681DM v.39 2010 / WF 553]
RC591.N497 2010
616.2'38061-dc22
2010029703
Bibliographic Indices. This publication is listed in bibliographic services, including Current Contents®.
Disclaimer. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s).The appearance of advertisements in the book is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Drug Dosage. The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
© Copyright 2010 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)
www.karger.com
Printed in Switzerland on acid-free and non-aging paper (ISO 9706) by Reinhardt Druck, Basel
ISSN 1422-2140
ISBN 978-3-8055-9566-7
e-ISBN 978-3-8055-9567-4
 
Contents
Corresponding authors
Foreword
Preface
Introduction
_______________
New drugs and targets for asthma and COPD
Trevor T. Hansel and Peter J. Barnes
Bronchodilators
_______________
Indacaterol: A new once-daily long-acting β2-adrenoceptor agonist (LABA)
Jutta Beier, Alexandre Trifilieff and Mark Higgins
Aclidinium bromide, a novel long-acting muscarinic antagonist (LAMA)
Amadeu Gavaldà and Esther Garcia-Gil
Dual-pharmacology bronchodilators for the treatment of COPD
John R. Jacobsen, Jayashree Aiyar, Sharath Hegde, Adam Hughes and Mathai Mammen
IgE- and epithelial-directed approaches
_______________
IgE-directed approaches: A general strategy for the treatment of atopic diseases
Franz Kricek
Therapy directed against thymic stromal lymphopoietin (TSLP)
Matthew J. Edwards
T-cell co-stimulator blockade
_______________
ICOS and B7RP-1: Novel targets for monoclonal antibodies
Gianluca Carlesso, Anthony J. Coyle and Ronald Herbst
Pattern recognition receptors
_______________
Toll-like receptor 2 as a therapeutic target in lung disease
Jane A. Mitchell, Rosalinda Sorrentino, Neil Cartwright and Mark Paul-Clark
Toll-like receptor 3
Michael Carty and Andrew Bowie
Toll-like receptor 4
Ian Sabroe
Toll-like receptor 7 and 8 agonists
Hanna Harant
Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy
Joel N. Kline and Arthur M. Krieg
Cytokines
_______________
IL-5-directed approaches in the treatment of eosinophil-driven disease
Richard Marshall and Isidore Faiferman
Monoclonal antibody therapy directed against interleukin-5 receptor a: MEDI-563
Roland Kolbeck, Masamichi Koike, Kazuhiro Kawasaki, Katsumasa Iwashita, George L. Spitalny, Nobuo Hanai, Peter A. Kiener, David Gossage, Nestor A. Molfino and Anthony J. Coyle
IL-4- and IL-13-directed approaches
Larry Borish, John W. Steinke, Marion Kasaian and Samuel J. Goldman
Aerovant (recombinant human interleukin-4 variant)
Malinda V. Longphre and Rick W. Fuller
An anti-interleukin-13 receptor α1 antibody for the treatment of asthma
Maria Elena Fuentes and Karim Dabbagh
Interleukin-7-directed approaches
Zaiba Shamim, Klaus Müller and Lars P. Ryder
Monoclonal antibody therapy directed against interleukin-9: MEDI-528
Alison A. Humbles, Jennifer L. Reed, Joseph Parker, Peter A. Kiener, Nestor A. Molfino, Roland Kolbeck and Anthony J. Coyle
Targeting interleukin-17 in the lungs
Stefan Ivanov and Anders Lindén
Chemokines
_______________
Chemokine CCR3 antagonists
Ash Bahl, Brian Springthorpe and Rob Riley
Therapeutic potential of CCR4 antagonists
David Hall, Alison Ford and Simon Hodgson
Adhesion molecules
_______________
Very late activation antigen-4 (VLA-4) antagonists
Peter Vanderslice and Darren G. Woodside
Selectin antagonists and their potential impact for the treatment of inflammatory lung diseases
Ewald M. Aydt, Daniel Bock and Gerhard Wolff
Mediator receptor antagonists
_______________
Histamine H 4 receptor antagonists
Paul J. Dunford and Robin L.Thurmond
Antagonists of the prostaglandin D 2 receptor CRTH2
Roy Pettipher and Trevor T. Hansel
Enzyme inhibitors
_______________
5-Lipoxygenase inhibition
Jaime L. Masferrer, Craig Wegner and Matt Graneto
Utility of cytosolic phospholipase A2a (cPLA2α) inhibitors in the treatment of asthma
James D. Clark and Cara M.M. Williams,
Antioxidants
_______________
Antioxidant therapeutic strategies
Paul Kirkham and Irfan Rahman
Protease inhibitors
_______________
Small-molecule neutrophil elastase inhibitors as therapies for respiratory disease
Mary F. Fitzgerald
The role of MMP-9 and MMP-12 inhibitors in inflammation
S. Wong, M.A Birrell, M.G. Belvisi, K. Stenvall and C.P. Bertrand
α 1 -Antitrypsin therapy
Philip J. Barr and Philip A. Pemberton
Inhibitors of fibrosis and vessels
_______________
Proteinase-activated receptor-1 inhibitors
Rachel C. Chambers
Integrin-mediated transforming growth factor-β activation
Gisli Jenkins and Dean Sheppard
Small-molecule inhibitors of transforming growth factor-β type I receptor kinase (ALK5)
Darren H. Wong and Linda S. Higgins
Serum amyloid P: A novel antifibrotic agent with therapeutic potential
Mark L. Lupher, Jr. and W. Scott Willett
Inhibitors of cell signaling and transcription
_______________
Phosphodiesterase type 4 (PDE4) inhibition: The search for effective therapy with minimal side effects
Mike Yeadon, Nick Clarke and Jon Ward
Therapy directed against c-kit (CD117) and PDGF transmembrane receptor tyrosine kinases
Christoph Walker, David Rodman and Trevor T. Hansel
Syk kinase inhibitors
Jane Denyer and Vipul Patel
Targeting protein kinase C-θ for asthma
Divya Chaudhary, Diane H. Boschelli and Marion T. Kasaian
Nucleic acid therapy
_______________
A multitargeted antisense therapy directed at CCR3 and the common β-chain of IL-3/IL-5/GM-CSF
Luc Paquet, Paolo Renzi, Nicolay Ferrari and Mark Parry-Billings
Author Index
Subject Index
 
Corresponding authors
Ash Bahl
Discovery Director New Opportunities
AstraZeneca R&D Charnwood
Bakewell Road
Loughborough, Leics LE11 5RH (UK)
Tel.[phone]
Fax [phone]
E-Mail [e-mail]
Philip J. Barr
Arriva Pharmaceuticals
1010 Atlantic Avenue
Alameda, CA 94501 (USA)
E-Mail [e-mail]
Maria G. Belvisi
Head, Respiratory Pharmacology Group
Airway Disease Section
National Heart & Lung Institute
Faculty of Medicine
1st Floor, Room 109
Sir Alexander Fleming Building (SAF)
South Kensington Campus
Exhibition Road
Imperial College London
London SW7 2AZ (UK)
Tel. [phone]
Fax[phone]
E-Mail [e-mail]
Daniel Bock
Director Preclinical R&D
Acting Dir